Results 101 to 110 of about 38,997 (290)

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström   +10 more
wiley   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

open access: yes, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B.   +7 more
core   +2 more sources

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg   +5 more
wiley   +1 more source

Sulfonylureas in type 2 diabetes mellitus: Current evidence, conflicts and clinical implications

open access: yesNigerian Journal of Medicine, 2017
INTRODUCTION: We sought to explore the current state of evidence on sulfonylurea therapy in type 2 diabetes mellitus (T2DM) and critically examine the recommendations of major practice guidelines,and the overall ramifications of the issues thereof in ...
Chiedozie Kenneth Ugwoke   +3 more
doaj   +1 more source

Sulfonylureas.

open access: yesJPMA. The Journal of the Pakistan Medical Association, 2015
This review describes the basic and clinical pharmacology of sulfonylureas. It undertakes a balanced assessment of the advantages and limitations of sulfonylureas, and compares the use of various sulfonylureas in different clinical situations. The authors suggest pragmatic guidance to facilitate safe and effective use of this class of drugs, and thus ...
Sanjay, Kalra, Yashdeep, Gupta
openaire   +1 more source

Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D).
Rakesh Sahay   +22 more
wiley   +1 more source

Sulfonylurea Receptor Pharmacology Alters the Performance of Two Central Pattern Generating Circuits in Cancer borealis

open access: yesFunction
Neuronal activity and energy supply must maintain a fine balance for neuronal fitness. Various channels of communication between the two could impact network output in different ways.
Sonal Kedia   +3 more
doaj   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang   +8 more
wiley   +1 more source

Diabetic foot ulcer‐related amputation is associated with twofold increased risk of cardiovascular disease: A Korean National Health Information Database Study

open access: yesJournal of Diabetes Investigation, EarlyView.
Data/Design: Nationwide, population‐based longitudinal cohort using the Korean National Health Insurance Service health checkup database (index 2009–2012) with follow‐up through December 31, 2018. Population/Exposure: Adults with diabetes (N = 1,229,689); DFU‐related amputation at baseline (n = 1,486) vs no DFU‐related amputation.
Jinsun Jang   +11 more
wiley   +1 more source

ChREBP drives β‐cell proliferation under metabolic stress but not in pregnancy‐induced β‐cell expansion

open access: yesJournal of Diabetes Investigation, EarlyView.
ChREBP is a context‐dependent regulator of adaptive β‐cell proliferation. It plays a pivotal role in driving β‐cell expansion under pathophysiological metabolic stress, such as insulin resistance and hyperglycemia, but has a limited role during physiological expansion in pregnancy.
Sodai Kubota   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy